CARDAMYST Sales of $238,000 in 1Q:26; Phase III AFib-RVR Trial Initiated

Research evidence excerpt

CARDAMYST Sales of $238,000 in 1Q:26; Phase III AFib-RVR Trial Initiated

ients by ~400 prescribers through April. CARDAMYST coverage currently includes Form 10Q as of May 13th + PFWs

over 25% of the U.S. commercially insured population, and Milestone has secured a Market Cap. (mil) US$242.4

national formulary agreement with Express Scripts. We now conservatively forecast U.S. Total Assets ($mil) 194

CARDAMYST sales of $6.86 million in 2026 and $26.3 million in 2027. Milestone owes Avg Daily Vol (000) 1,948

Book Value/Share US$0.26 RTW royalties of 7.0% on annual sales up to $500 million, 4.0% on $500-800 million

Price/Book 662%

and 1.0% on >$800 million. The NDA was accepted by the NMPA in China in January Net Cash Per Share US$0.34

where etripamil will be marketed by Everest Medicine. The EMA has accepted the MAA 1Q:26 cash less convertible debt and

for TACHYMIST in PSVT with potential approval in 1H:27. Milestone plans to partner royalty financing obligation

etripamil outside the U.S. and China for both PSVT and AFib. Debt to Total Capital 70.4%

Div (ann) NA

• Phase III AFib-RVR Trial Start. CARDAMYST offers a safe, rapid and effective therapy Fiscal Year End Dec

to revert AFib-RVR back to normal sinus rhythm. In the Phase II ReVeRA-201 study Price Performance - 1 Year

(N=70), CARDAMYST lowered HR by 29.9 bpm at 13 minutes (p<0.0001) and improved

symptoms (p=0.0002). Milestone has initiated the Phase III ReVeRA-301 trial (N=750) USD 3.5

with enrollment starting in 2H:26. The trial will analyze 150-200 AFib-RVR events at the

70mg CARDAMYST vs. placebo (1:1) on reduction in ventricular rate as the primary 3

endpoint. Milestone anticipates reporting data in 2H:28. AFib-RVR is a larger patient 2.5

population than PSVT with blockbuster potential. 2